2023 Advances in Breast Cancer Treatment: Breakthroughs from ASCO Clinical Trials
The 2023 American Society for Clinical Oncology (ASCO) annual clinical meeting in cancer research showcased groundbreaking advances in Breast Cancer treatment. Among the plethora of clinical trial updates, two stand out as game-changers. Firstly, CDK4/6 inhibitors are taking a prominent position in Breast Cancer therapy. Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) are enzymes important in cell division. CDK4/6 inhibitors are drugs designed to interrupt the growth of cancer cells. CDK4/6 inhibitors are used in combination with hormone therapy to treat some Breast Cancers. These inhibitors block cancer cells' growth cycle, preventing cancer progression, and were initially developed as a treatment option for endocrine therapy-resistant Breast Cancer. Palbociclib (Ibrance®) received American FDA approval in 2015, followed by ribociclib (Kisqali®) and abemaciclib (Verzenio®) in 2017 and in the UK NICE approved it in 2018. Researchers presented...